Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (RESPONSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01213667
Recruitment Status : Unknown
Verified October 2016 by Philipp S. Muether, University of Cologne.
Recruitment status was:  Active, not recruiting
First Posted : October 4, 2010
Last Update Posted : October 26, 2016
Sponsor:
Information provided by (Responsible Party):
Philipp S. Muether, University of Cologne

Brief Summary:
To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

Condition or disease Intervention/treatment Phase
Macular Degeneration Drug: Ranibizumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations
Study Start Date : January 2010
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
ranibizumab as needed Drug: Ranibizumab
upload (three monthly injections), re-treatment as needed
Other Name: Lucentis




Primary Outcome Measures :
  1. Visual acuity [ Time Frame: 2 years ]
    Change in visual acuity within the observation period


Secondary Outcome Measures :
  1. Association between treatment response and genotype [ Time Frame: 2 years ]
  2. Changes in OCT central retinal thickness / retinal volume [ Time Frame: 2 years ]
  3. Association between treatment application delay and visual outcome [ Time Frame: 2 years ]
  4. Association between re-treatment necessity / frequency and intraocular cytokine profiles [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • active subfoveal CNV related to exudative age-related macular degeneration (all subforms)
  • age > 60 years
  • visual acuity > 20/400
  • no previous treatment for AMD

Exclusion Criteria:

  • any previous AMD therapy
  • other CNV types (myopic, parapapillary)
  • contraindication for ranibizumab treatment
  • prior study participation for AMD
  • pregnancy / premenopausal women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01213667


Locations
Layout table for location information
Germany
University Center of Ophthalmology
Cologne, NRW, Germany, 50924
Sponsors and Collaborators
University of Cologne
Investigators
Layout table for investigator information
Principal Investigator: Philipp S Muether, MD Center of Ophthalmology, University of Cologne

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Philipp S. Muether, MD, PhD, University of Cologne
ClinicalTrials.gov Identifier: NCT01213667    
Other Study ID Numbers: RESPONSE2010
First Posted: October 4, 2010    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Ranibizumab
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antineoplastic Agents, Immunological